You are here: Industry Insights > Regeneron

News List

Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment europeanpharmaceuticalreview
September 17, 2020
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
Further clinical trials testing Kevzara as COVID-19 therapy to be halted europeanpharmaceuticalreview
September 03, 2020
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
Kevzara fails in PhIII COVID-19 trial pharmatimes
September 02, 2020
Sanofi and Regeneron's rheumatoid arthritis drug Kevzara (sarilumab) has failed to hit targets in a late-stage trial involving patients hospitalised with COVID-19, signalling the end of its development in this area.
Regeneron to create 400 jobs to support manufacturing in Ireland pharmaceutical-technology
August 31, 2020
Regeneron Pharmaceuticals has plans to add more than 400 new jobs to its Industrial Operations and Product Supply (IOPS) campus in Limerick, Ireland.
Top Pharma & Biopharma Quarterly Results contractpharma
August 26, 2020
Pfizer: 2Q Revenues: $11.8 billion (-11%). 2Q Earnings: $3.4 billion (-32%). YTD Revenues: $23.8 billion (-10%). YTD Earnings: $6.8 billion (-24%)...
Roche teams up with Regeneron on Covid-19 therapy pharmaceutical-technology
August 21, 2020
Roche has partnered with Regeneron Pharmaceuticals to develop, manufacture and distribute the latter’s antiviral antibody combination, REGN-COV2, as a potential treatment of Covid-19.
Roche, Regeneron Partner to Increase Global Supply of REGN-COV2 contractpharma
August 20, 2020
To develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination to treat COVID-19.
FDA Accepts Evinacumab BLA for HoFH americanpharmaceuticalreview
August 17, 2020
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a Biologics License Application (BLA) for evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous familial ...
Regeneron, NIAID Begin REGN-COV2 Phase 3 COVID-19 Prevention Trial americanpharmaceuticalreview
July 15, 2020
Regeneron Pharmaceuticals announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19.
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients worldpharmanews
July 14, 2020
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page